Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8048420 | 0.98 | ALDH1A1 (0.50) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| SCHEMBL222908 | 0.86 | NR4A1 (0.60) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| SCHEMBL27356901 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| SCHEMBL5352931 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| Acridine SCHEMBL31147690 | 0.84 | NR4A1 (0.58) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| Hydrochloric Acid SCHEMBL9083721 | 0.84 | NR4A1 (0.58) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| Water SCHEMBL7769203 | 0.84 | NR4A1 (0.58) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| Acridine SCHEMBL29774329 | 0.84 | NR4A1 (0.58) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| SCHEMBL8850857 | 0.84 | NR4A1 (0.58) | ALDH1A1KMT2AKDM4ERAB9AHPGD | |
| SCHEMBL154847 | 0.83 | ALDH1A1 (0.64) | ALDH1A1KMT2AKDM4ERAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113773299-B | Acridine salt derivative and synthesis method and application thereof | 上海敏韬医药科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-7718576-B2 | Peroxide-based chemiluminescent assays and chemiluminescent compounds used therein | WALDROP III ALEXANDER A | 2010-05-18 | — | — | US | disclosed |
| EP-1019379-B1 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | MAINE MEDICAL CT (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20030219844-A1 | Peroxide-based chemiluminescent assays and chemiluminescent compounds used therein | MAINE MEDICAL CENTER | 2003-11-27 | — | — | US | disclosed |
| US-6423497-B1 | LABELING PREFERENTIAL NUCLEOTIDE SEQUENCES; OBTAIN NUCLEIC ACIDS, INCUBATE IN AMPLIFICATION MIXTURE WITH LABEL AND BINDING AGENT, EXPOSE TO LIGHT, RECOVER PRODUCT | APPLIED GENE TECHNOLOGIES, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-1192272-A2 | METHOD OF LABELING A NUCLEIC ACID AMPLICON WITH SIMULTANEOUS CONTAMINATION PREVENTION | Applied Gene Technologies, Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1019379-A4 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | MAINE MEDICAL CT (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6187566-B1 | COMPLEXES | APPLIED GENE TECHNOLOGIES, INC. | 2001-02-13 | — | — | US | disclosed |
| WO-2000053809-A2 | METHOD OF LABELING A NUCLEIC ACID AMPLICON WITH SIMULTANEOUS CONTAMINATION PREVENTION | APPLIED GENE TECHNOLOGIES, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| EP-1019379-A1 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | Maine Medical Center (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999009012-A1 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | MAINE MEDICAL CENTER (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5864044-A | Syntheses of trisulfonated phthalocyanines and their derivatatives using boron (111) subphthalocyanines as intermediates | UNIVERSITE DE SHERBROOKE (CA) | 1999-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219844-A1 | Peroxide-based chemiluminescent assays and chemiluminescent compounds used therein | CBR1, CBR3, NR2E3 | ALDH1A1 461/4885KMT2A 3611/4885KDM4E 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.